Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.46 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.43 |
| ▸ | ALKBH1 | Q13686 | 4/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrous Acid SCHEMBL29248972 | 0.97 | EGLN1 (0.44) | EGLN1ALKBH2GRM4ALKBH1RIPK2 | |
| SCHEMBL29248924 | 0.91 | EGLN1 (0.39) | EGLN1ALKBH2GRM4ALKBH1RIPK2 | |
| SCHEMBL29248969 | 0.91 | EGLN1 (0.40) | EGLN1ALKBH2GRM4ALKBH1RIPK2 | |
| SCHEMBL24257499 | 0.88 | GRM4 (0.50) | ALKBH2GRM4ALKBH1RIPK2MAPT | |
| SCHEMBL26259966 | 0.85 | ALDH1A1 (0.39) | EGLN1ALKBH2GRM4RIPK2MAPT | |
| Nitrous Acid SCHEMBL29248888 | 0.85 | GRM4 (0.48) | ALKBH2GRM4ALKBH1RIPK2MAPT | |
| SCHEMBL24257566 | 0.83 | GRM4 (0.44) | GRM4ALKBH1RIPK2MAPT | |
| SCHEMBL24257812 | 0.82 | GRM5 (0.46) | EGLN1ALKBH2GRM4RIPK2GRM5 | |
| SCHEMBL29248974 | 0.82 | EGLN1 (0.53) | EGLN1ALKBH2GRM4GRM5MAPT | |
| SCHEMBL24257808 | 0.81 | PDK2 (0.39) | ALKBH1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-116670131-A | PHD inhibitor compounds, compositions, and methods of use | 阿克比治疗有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | EGLN1 19/4885ALKBH2 4576/4885GRM4 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.